Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin D1(+), and CD10(-)
Patient has persistent / recurrent disease after standard chemotherapy
Patient has not received either standard or investigational drugs within the last 3 weeks
Available frozen tumor tissue obtained since completion of last prior therapy (rebiopsy if needed)
Patient has measurable disease as defined by a tumor mass \> 1.5 cm in one dimension
Age \> 18 years
Absolute granulocyte count \> 1000 cells/mm3
Platelet count \> 50,000 cells/mm3
Creatinine \< 2.0 x ULN
Total bilirubin \< 2.0 x ULN
Patient has KPS \> 50%
Patient agrees to use birth control if of reproductive potential
You may not be if
Known central nervous system (CNS) involvement by lymphoma
Known HIV disease
Known peripheral neuropathy \> grade 2
Patient is pregnant or nursing
Patient has had major surgery within the last 3 weeks
Patient is receiving other investigational drugs
Clareo Health | Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
